Gelteq Appoints Matthew Jones as Head of Sports Performance
24 1월 2025 - 10:00PM
Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a global
biotechnology company that specializes in the formulation,
development, and manufacturing of ingestible gel technology,
announced today the appointment of Matthew Jones as Head of Sports
Performance. He will oversee the growth, outreach, and customer
strategy of Gelteq’s sports vertical.
“The sports industry is one of a number of key
areas that Gelteq’s unique formulation can pose a significant
improvement to nutrient delivery over traditional methods,” said
Nathan Givoni, Co-Founder and CEO of Gelteq. “Matthew’s pedigree
aligns perfectly for this position with his global experience in
high-level sports training and sports dietetics and we are excited
to grow the adoption of our gel-based delivery platform in the
sports vertical under his guidance.”
“I look forward to beginning this journey toward
greater adoption of the gel-based platform for better nutrient and
supplement absorption with a focus on sports clientele,” Jones
said. “I greatly enjoy simplifying complex nutrition science, and
with Gelteq’s unique platform, we have the opportunity to expand on
important nutrition science while providing a solution to help
athletes improve their nutrition with a better delivery
system.”
Mr. Jones is a leading
internationally-experienced sports dietitian who currently works as
Head of Nutrition with the United Arab Emirates Football
Association and as a consultant to the Boston Celtics in the
National Basketball Association. He has more than 12 years of
applied experience in elite sports, having worked in international
football, the English Premier League, the Women’s Super League, and
NCAA Division I sports. Jones holds a Master’s Degree in Nutrition
Science from University of Chester and is registered with the
British Dietetic Association, Sport Nutrition Register.
About Gelteq
Limited:Headquartered in Melbourne, Australia, Gelteq
(NASDAQ: GELS) is a global biotechnology company focused on
developing and commercializing white label gel-based delivery
solutions for prescription drugs, nutraceuticals, pet care, and
other products. Gelteq advances and commercializes its delivery
solutions within five core verticals: pharmaceuticals,
over-the-counter medications, nutraceuticals, animal medications,
and sports nutrition. The Company’s unique formulation directly
addresses the issues associated with traditional drug delivery
methods such as difficulty swallowing, taste of unpalatable
ingredients, and dosage control. For more information,
visit www.gelteq.com.
Forward-Looking
Statements Certain statements in this press release
may constitute “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Forward-looking
statements contained in this press release may be identified by the
use of words such as “anticipate,” “believe,” “contemplate,”
“could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,”
“plan,” “potential,” “predict,” “project,” “suggest,” “target,”
“aim,” “should,” "will,” “would,” or the negative of these words or
other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are
based on Gelteq’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict,
including risks related to the timing and fulfilment of current and
future orders relating to Gelteq’s products, the success of new
programs, the ability to implement a new strategic plan and the
success of a new strategic plan. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. For a further discussion of risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Gelteq in general, see the risk factors
in the Annual Report on 20-F filed on November 15, 2024. All
such forward-looking statements speak only as of the date they are
made, and Gelteq undertakes no obligation to update or revise these
statements, whether as a result of new information, future events
or otherwise.
Contact:CORE
IR516-222-2560PR@gelteq.com
Gelteq (NASDAQ:GELS)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Gelteq (NASDAQ:GELS)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025